Delivery Order SPE2DB20D1100-SPE2DB25FE0U8
- Not listed
- The Defense Logistics Agency awarded a $5,864.45 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a $1,037.40 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors under a firm fixed price contract with an ultimate completion date of July 15, 2025. The award, issued on July 14, 2025, represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention and treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $1,309.49 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on May 20, 2025, with an ultimate completion date of May 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication, reflecting the company's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This non-set-aside, competitively awarded contract was issued on September 16, 2025, with an ultimate completion date of September 17, 2025, and reflects a firm fixed-price delivery order structure. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a $19,429.58 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 19, 2025, with completion targeted for September 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication used in military and federal healthcare systems to treat...
- The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitively awarded, firm fixed-price delivery order was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a $2,348.61 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 4, 2025, with a completion date of September 5, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide monoclonal antibody used in migraine prevention, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,530.62 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of September 17, 2025. This competitive award uses firm fixed pricing with no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $1,250.34 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors. This is a firm fixed price, non-set-aside contract completed on September 4, 2025. The order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with DLA, with performance fulfilled at the company's Conshohocken, Pennsylvania location. Emgality is a migraine prevention medication, reflecting the breadth of...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0U8Delivery Order
The Defense Logistics Agency awarded a $1,729.00 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors under a firm fixed price contract. This non-competitive, non-set-aside delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication, reflecting the government's ongoing need for specialized pharmaceutical products to support military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, a $999.99 billion prime vehicle designated SPE2DX and running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to fulfill diverse medical supply requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/14/25 |